Relationship between serum lipids and endometrial cancer: A systematic review and meta-analysis

Document Type : Review Article

Authors

1 PhD Student of Reproductive Health, Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Assistant Professor, Department of Midwifery and Reproductive Health, Midwifery and Reproductive Health Research Center, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Professor, Department of Obstetrics and Gynecology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Associate Professor, Department of Midwifery and Reproductive Health, Midwifery and Reproductive Health Research Center, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Introduction: Endometrial cancer is the fifth most common cancer in females worldwide. One of the most important risk factors for endometrial cancer is obesity. The relationship between obesity and endometrial cancer is due to the exposure to biological agents produced in the adipose tissue. In general, the presence of lipids is essential for the growth and development of cancer cells. Given the limited studies regarding the association between lipid profile and endometrial cancer and their contradictory results, the present  systematic review and meta-analysis was conducted to bridge this gap.
Methods: For the purpose of the study, the studies related to the issue of interest and published until November 2017 were searched in Google Scholar search engine and several international databases, including PubMed, Elsevier, Scopus, web of knowledge, and SID, by two authors independently. The search process was accomplished using the following keywords alone or in combination: "lipid", "lipoprotein", "cholesterol", "LDL cholesterol", "HDL cholesterol", "triglyceride", "dyslipidemia", "endometrial cancer", "endometrial carcinoma", and "endometrial neoplasm". The MOOSE instruction was employed to perform and report this meta-analysis. The data were analyzed using Stata statistical software, version 14.
Results: A total of 369,649 subjects participated in the eight reviewed studies, 2,809 of whom were inflicted with endometrial cancer, while the rest were healthy. The combined estimates of the relative risk for total cholesterol and high-density lipoprotein (HDL) cholesterol were 1.21 (95% CI: 0.98-1.45) and 1.11 (95% CI: 0.74-1.48), respectively. This value was obtained as 1.09 (95% CI: 1.10-1.71) and 1.47 (95% CI: 1.10-1.85) for the highest low-density lipoprotein (LDL) and triglyceride levels, respectively, compared to the lowest levels.
Conclusion: As the findings indicated, serum triglyceride levels were associated with endometrial cancer. However, this cancer showed no relationship with total cholesterol, HDL, and LDL levels.

Keywords

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5):E359-86.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1):5-29.
  3. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11(12):1531-43.
  4. von Gruenigen VE, Gil KM, Frasure HE, Jenison EL, Hopkins MP. The impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol 2005; 193(4):1369-75.
  5. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K, Tanaka K. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol 2010; 119(1):65-9.
  6. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101(1):48-60.
  7. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol Res 2006; 55(3):233-44.
  8. Cymbaluk A, Chudecka-Głaz A, Rzepka-Górska I. Leptin levels in serum depending on Body Mass Index in patients with endometrial hyperplasia and cancer. Eur J Obstet Gynecol Reprodu Biol 2008; 136(1):74-7.
  9. Forney JP, Milewich L, Chen GT, Garlock JL, Schwarz BE, Edman CD, et al. Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia. J Clin Endocrinol Metab 1981; 53(1):192-9.
  10. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 2014; 45(1):26-38.
  11. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990; 31(7):1149-72.
  12. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-α content and enhancing prostaglandin release. Circ Res 2003; 92(3):330-7.
  13. Kimura Y, Sumiyoshi M. High-fat, high-sucrose, and high-cholesterol diets accelerate tumor growth and metastasis in tumor-bearing mice. Nutr Cancer 2007; 59(2):207-16.
  14. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010; 70(20):8117-26.
  15. Lindemann K, Vatten LJ, Ellstrøm‐Engh M, Eskild A. Serum lipids and endometrial cancer risk: results from the HUNT‐II study. Int J Cancer 2009; 124(12):2938-41.
  16. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjønneland A, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007; 14(3):755-67.
  17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9):603-5.
  18. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004; 48(8):2787-92.
  19. Higgins J, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414):557-60.
  20. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. New Jersey: John Wiley & Sons; 2011.
  21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109):629-34.
  22. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 2003; 104(6):669-76.
  23. Fortner RT, Hüsing A, Kühn T, Konar M, Overvad K, Tjønneland A, et al. Endometrial cancer risk prediction including serum‐based biomarkers: results from the EPIC cohort. Int J Cancer 2017; 140(6):1317-23.
  24. Hirasawa A, Makita K, Akahane T, Yokota M, Yamagami W, Banno K, et al. Hypertriglyceridemia is frequent in endometrial cancer survivors. Jap J Clin Oncol 2013; 43(11):1087-92.
  25. Tawfik TA, Elsabaa BM, El-Neily DA, El-Tawab SS, Ebrahim HA. The impact of metabolic syndrome on the clinical profile and tumor characteristics of endometrial carcinoma. Int J Reprod Contracept Obstet Gynecol 2016; 5(11):3696-703.
  26. Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME, Brinton LA. Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER–medicare linked database. Cancer Epidemiol Biomarkers Prev 2015; 24(1):261-7.
  27. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. New York: Springer; 2014.
  28. Zhao J, Lyu C, Gao J, Du L, Shan B, Zhang H, et al. Dietary fat intake and endometrial cancer risk: a dose response meta-analysis. Medicine 2016; 95(27):e4121.
  29. Jiang L, Hou R, Gong TT, Wu QJ. Dietary fat intake and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. Sci Rep 2015; 5:16693.
  30. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Dietary lipids and endometrial cancer: the current epidemiologic evidence. Cancer Causes Control 2007; 18(7):687-703.
  31. Zhao Y, Wang H, Pan Y, Li N, Bian C. Association of lipid profile levels in premenopausal and postmenopausal women with breast cancer: a meta-analysis. Int J Clin Exp Med 2016; 9(2):552-63.
  32. Qadir MI, Malik SA. Plasma lipid profile in gynecologic cancers. Eur J Gynaecol Oncol 2008; 29(2):158-61.
  33. Chandler PD, Song Y, Lin J, Zhang S, Sesso HD, Mora S, et al. Lipid biomarkers and long-term risk of cancer in the women’s health study. Am J Clin Nutr 2016; 103(6):1397-407.
  34. Ni H, Liu H, Gao R. Serum lipids and breast cancer risk: a meta-analysis of prospective cohort studies. PloS One 2015; 10(11):e0142669.
  35. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007; 335(7630):1134.
  36. Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol 2013; 2013:823849.
  37. Dossus L, Lukanova A, Rinaldi S, Allen N, Cust AE, Becker S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort--a factor analysis. Am J Epidemiol 2013; 177(8):787-99.
  38. Sponholtz TR, Palmer JR, Rosenberg L, Hatch EE, Adams-Campbell LL, Wise LA. Body size, metabolic factors, and risk of endometrial cancer in black women. Am J Epidemiol 2016; 183(4):259-68.
  39. Rui S, Hong-bo WA. Research of the correlation between lipid metabolic and endometrial cancer. J Int Obstet Gynecol 2015; 42(2):133-5.
  40. Friedenreich CM, Biel RK, Lau DC, Csizmadi I, Courneya KS, Magliocco AM, et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2011; 20(11):2384-95.
  41. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995; 122(5):327-34.
  42. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007; 86(3):s836S-42.
  43. Laisupasin P, Thompat W, Sukarayodhin S, Sornprom A, Sudjaroen Y. Comparison of serum lipid profiles between normal controls and breast cancer patients. J Lab Physicians 2013; 5(1):38-41.
  44. Tania M, Khan M, Song Y. Association of lipid metabolism with ovarian cancer. Curr Oncol 2010; 17(5):6-11.
  45. Ghahremanfard F, Mirmohammadkhani M, Shahnazari B, Gholami G, Mehdizadeh J. The valuable role of measuring serum lipid profile in cancer progression. Oman Med J 2015; 30(5):353-7.
  46. Perrotti F, Rosa C, Cicalini I, Sacchetta P, Del Boccio P, Genovesi D, et al. Advances in lipidomics for cancer biomarkers discovery. Int J Mol Sci 2016; 17(12):1992.
  47. Bailwad SA, Singh N, Jani DR, Patil P, Singh M, Deep G, et al. Alterations in serum lipid profile patterns in oral cancer: correlation with histological grading and tobacco abuse. Oral Health Dent Manag 2014; 13(3):573-9.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 21, Issue 5
July 2018
Pages 87-96

Files

Share

How to cite

Statistics